) Financial costs 0.02 0.01 0.01 dt -6t 0.02 0.01 0.01 87.87 Total Expenses 5l 82 35.91 1.91 5.29 2a EO 36.24 1.34 3.70 Profit before share loss from investment in joint venture and income tax 2.83 4.74 (1 .91
and Service 2,425.0 96.4 2,852.6 96.2 Franchise Fees Income 56.5 2.2 69.6 2.3 Other Income 33.7 1.3 42.5 1.4 Total Revenue 2,515.2 100.0 2,964.7 100.0 Remark: (1) Percentage of Total Revenue For the
audited by the independent auditor as follows: Statements of Comprehensive Income for the 3rd Quarter and 9 months of 2018 Note: During 1Q’17, the subsidiary has recorded income incurred from deferred tax
recognized RH’s and AVA’s sales of electricity in the entire third quarter of 2020, while in the third quarter of 2019, it recognized sales of electricity only from ETC’s operations. Summary of income
with the same period of last year. The income statement in brief is presented as following: DOD BIOTECH PUBLIC COMPANY LIMITED เลขที ่111 หมู่ที ่2 ต ำบลท่ำจีน อ ำเภอเมืองสมุทรสำคร จังหวดัสมุทรสำคร 74000
Company have neither ability to manage finished goods (HRC) nor trade negotiation. Due to the Company had no choice but necessary to sell them just for generating income circulating used in the business
comprehensive income for the year ended 31 December (Unit : Million Baht) 2017 2016 Change % Change Operating revenue 1,580.25 1,411.68 168.58 11.94% Operating cost 1,335.73 1,217.44 Gross profit 244.53 194.24
audited by the independent auditor as follows: Statements of Comprehensive Income for the Fourth Quarter and Year Ended December 31, 2017 Note: During 1Q17, the Company’s subsidiary has recorded income
. % MB. % MB. % Rental and Service Income 163.7 91.9% 155.0 90.3% -8.7 -5.3% Total Revenues 178.2 100.0% 171.7 100.0% -6.5 -3.6% Cost of Rental and Service 139.4 78.2% 134.8 86.3% -4.6 -3.3% Gross Profit
clarify operating performance of the Company three-month for the Quarter 2/2019 ended 30 June 2019 as the following: change Q2/2019 Q2/2018 increase (decrease) Sales 172.5 240.8 -28.4% Other income 17.8 0.6